November 16, 2007 -- China Biologic Products (OTCBB: CBPO) reported record financial results for Q3 even though shipments of its blood-based products were lower than the year earlier. The secret? Albumin and other plasma-based products are in short supply in China, forcing China officials to allow prices to climb. In fact, China Biologic said the price of one product skyrocketed 425%. Counterfeiting forced regulators to crack down on all producers, restricting supplies still further. More details...
